Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia.

Saskia Inniss,Konstantinos C Fragkos,Lisa Whitley,Rachel Wimpory,Eleanor Rebello,Ana Lisboa,Tanvi Khetan,Jasmine Hassan,Kate Simpson,Anisha Bhagwanani,Roser Vega,Ioanna Parisi,Paul Harrow,Edward Seward,Sara McCartney,Stuart Bloom,Andrew M Smith,Andrew Plumb,Farooq Z Rahman

Therapeutic advances in chronic disease（2023）

引用 0|浏览2

暂无评分

摘要

Ustekinumab is effective in non-bio-naïve CD patients with non-stricturing, non-penetrating disease with an unremarkable safety profile but may be less effective in those with penetrating disease, -ostomies and sarcopenia.

查看译文

关键词

Crohn's disease, persistence, sarcopenia, ustekinumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要